Sareum Holdings

LN: SAR

£56.4m market cap

1.73p last close

Sareum is a UK company with a discovery-stage oncology pipeline and a profitable fee-for-service business providing structure-based drug discovery.

Investment summary

The bulk of Sareum’s value rests on the late preclinical autoimmune therapy SDC-1801, with planned filing to start clinical development in H121 followed by possible exploratory clinical studies, if funding allows, from H221. This could open the way to a substantive partnering deal from Q222. Partnering could be helped if the related BMS therapeutic deucravacitinib gains FDA approval and blockbuster sales in psoriasis. Sareum could offer a partner a promising route to an autoimmune therapy with potentially broad indications.

Register to receive research on Sareum Holdings as it is published
Sector
Healthcare
Share price graph
Price performance
%
1m
3m
12m
Actual (13.8) 11.3 379.2
Relative* (14.0) 6.6 404.8
52-week high/low 2.5p/0.2p
*% relative to local index
Key management
Tim Mitchell CEO
John Reader CSO
Stephen Parker Non-executive chairman